Vectorite Biomedical

Vectorite Biomedical Net Margin

The Net Profit Margin of Vectorite Biomedical (4170.TWO) as of Nov 5, 2026 is 156.62 %. In the previous year, Net Profit Margin was -69.33 % — a change of -325.90% (higher).

Net Margin

156.62 %

YoY

-325.90%

Last updated:

Net Profit Margin of Vectorite Biomedical is 2025 156.62 % . Net Profit Margin of Vectorite Biomedical was 2024 -69.33 % . It decreases by -325.90% higher compared to the previous year.

For Vectorite Biomedical, the net margin of 156.6% is up versus 29.1% a few years ago.

The Vectorite Biomedical Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2018
-14.70 TWD
Jan 1, 2019
-340.11 TWD
Jan 1, 2020
-277.75 TWD
Jan 1, 2021
29.05 TWD
Jan 1, 2022
-61.55 TWD
Jan 1, 2023
-11.82 TWD
Jan 1, 2024
-69.33 TWD
Jan 1, 2025
156.62 TWD
The Vectorite Biomedical Net Margin history
YEARNet MarginYoY
156.62 %-325.90%
-69.33 %+486.62%
-11.82 %-80.80%
-61.55 %-311.86%
29.05 %-110.46%
-277.75 %-18.34%
-340.11 %+2,214.26%
-14.70 %-66.14%
-43.41 %-80.99%
-228.35 %-6.49%
-244.20 %-821.77%
33.83 %-4,935.21%
-0.70 %-87.82%
-5.75 %-40.10%
-9.59 %+81.21%
-5.29 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Vectorite Biomedical Stock analysis

What does Vectorite Biomedical do? Xinpin Biomedical Co., Ltd. established Xinpin Biomedical Group with the concept of “preventing problems before it happens” and is headquartered in Taipei, New Taipei. The firm offers a range of services including immune cell collection, processing and storage, cell preparation safety testing, anti-cancer immunity testing, original design manufacturer or contract development and manufacturing organization services, related medical consulting, and laboratory quality management. Its product portfolio features dendritic cell vaccines and natural killer cell preparations designed for cancer treatment. Products are mainly sold domestically. Vectorite Biomedical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vectorite Biomedical stock

Net Profit Margin of Vectorite Biomedical is 156.62 % in 2025.

Net Profit Margin of Vectorite Biomedical changed from -69.33 % to 156.62 %, representing a -325.90% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin Vectorite Biomedical since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Vectorite Biomedical with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Vectorite Biomedical

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Vectorite Biomedical